No description available.

Diss. (sammanfattning) Stockholm : Karol. inst., 2002. / Härtill 6 uppsatser.

Accurate determination of the in vitro kinetic parameters Km (Michaelis constant) and Ki (inhibition constant) is critical for the quantitative prediction of in vivo drug clearance and the magnitude of inhibitory drug interactions. A cause of inaccuracy in vitro arises from the assumption that all drug added to an incubation mixture is available for metabolism or inhibition. Many drugs bind non-specifically to the membrane of the in vitro enzyme source. The aims of this thesis were to: 1) investigate the comparative importance of lipophilicity (as log P), and pKa as determinants of the non-specific binding of drugs to human liver microsomes; 2) develop and validate an ANS fluorescence technique for measuring the non-specific binding of drugs to human liver microsomes; 3) characterise the non-specific binding of a large dataset of physicochemically diverse drugs using the ANS fluorescence procedure; 4) evaluate relationships between selected physicochemical characteristics and the extent of non-specific binding of drugs to human liver microsomes and; 5) computationally model the non-specific binding of drugs to discriminate between high binding (fu(mic) less than 0.5) and low binding (fu(mic) greater than 0.5) drugs. The comparative binding of the basic drugs atenolol (log P = 0.1; fu(mic) = 1.00), of propranolol (log P = 3.1; fu(mic) = 0.36 - 0.84), and imipramine (log P = 4.8; fu(mic) = 0.42 - 0.82) suggested that lipophilicity is a major determinant of non-specific binding. In contrast, the comparative binding of diazepam (pKa = 3.3; fu(mic) = 0.69 - 0.80), a neutral compound; and the bases propranolol (pKa = 9.5; fu(mic) = 0.36 - 0.84) and lignocaine (pKa = 9.5; fu(mic) = 0.98), indicated that pKa was not a determinant of the extent of non-specific binding. The non-binding of lignocaine, a relatively lipophilic base, was unexpected and confirmed by the non-binding of the structurally related compounds bupivacaine and ropivacaine. These results implicated physicochemical characteristics other than lipophilicity and charge as important for the non-specific binding of drugs to human liver microsomes. An assay based on 1-anilinonaphthalene-8-sulfonate (ANS) fluorescence was developed using the seven drugs employed in the initial study. Non-specific binding data from equilibrium dialysis and the ANS fluorescence methods were compared and a linear correlation (r2 = 0.92, p less than 0.01) was observed at drug concentrations of 100 and 200 micromolar. The approach was further validated by characterising the microsomal binding of nine compounds (bupropion, chloroquine, chlorpromazine, diflunisal, flufenamic acid, meclofenamic acid, mianserine, triflupromazine, and verapamil) using both binding methods (i.e. equilibrium dialysis and ANS fluorescence). A significant logarithmic relationship (r2 greater than or equal to 0.90) was demonstrated between fu(mic) and the modulus of ANS fluorescence for all drugs and for basic drugs alone at concentrations of 100 and 200 micromolar, while the acidic/neutral drugs showed a significant linear relationship (r2 greater than or equal to 0.84) at these two concentrations (p less than 0.01). The non binding of bupropion provided further evidence that physicochemical properties other than log P and charge were important for non-specific binding of drugs to human liver microsomes. The ANS fluorescence technique was then used to characterise the non-specific binding of 88 physicochemically diverse compounds. In general, acids and neutrals bound to a ‘low’ extent (fu(mic) greater than 0.5) whereas bases bound the full fu(mic) range (0.0001 to 1). Statistically significant relationships were observed between the non-specific binding of bases and log P, the number of hydrogen bond donors and hydrogen bond acceptors per molecule, and molecular mass. Preliminary in silico modeling of the dataset generated by the ANS fluorescence technique, using the program ROCS, provided discrimination of all but one (itraconazole) of the ‘high’ binding bases. However, there were 14 false positives, resulting in low overall prediction accuracy. Taken together, the studies conducted in this thesis provide important insights into the physicochemical factors that determine the non-specific binding of drugs to human liver microsomes.

Thesis (Ph. D.)--University of Alabama at Birmingham, 2007. / Title from first page of PDF file (viewed Feb. 7, 2008). Includes bibliographical references (p. 114-133).

Thesis (Ph. D.)--University of Washington, 1999. / Vita. Includes bibliographical references (leaves 163-179).

Vemurafenib is a potent serine/threonine kinase inhibitor and is registered as Zelboraf® for the treatment of metastatic melanomas harboring BRAFV600E mutations. There is a large individual variation in drug response and the side effects observed among patients treated with Zelboraf® has proven to be severe.  LC-MS/MS methods were developed to measure vemurafenib and its metabolites in human plasma for prediction of treatment outcome and side effects in order to individualize treatment with Zelboraf®.  A novel, rapid quantification method was developed for vemurafenib using a stable isotope labeled internal standard. The method was validated according to international guidelines with regard to calibration range, accuracy, precision, carry-over, dilution integrity, selectivity, matrix effects, recovery and stability. All parameters met the set acceptance criteria.  The first method suitable for quantifying vemurafenib metabolites in human plasma is presented. Lacking commercially available reference substances, human liver microsomes were used to produce the metabolites. In patient samples at steady-state five previously in vitro identified metabolites were quantified for the first time.

Polychlorinated biphenyls (PCBs) continue to pose a health concern because of their predominance in the diet and air as well as in environmental samples and humans. PCB congeners with 3 or 4 chlorine substituents in ortho position have been associated with neurodevelopmental disorders. Hydroxylated metabolites (OH-PCBs) of these PCBs are also potentially toxic to the developing brain. Metabolism studies have mainly focused on animal models. However, preliminary data from this dissertation work have revealed PCB metabolism differences between laboratory animal models and humans in terms of metabolite profiles, chiral signatures. More concerning, biotransformation of chiral PCBs is poorly investigated in humans. The objective of this dissertation research was to study the biotransformation of chiral and prochiral PCBs to chiral hydroxylated metabolites in humans and rats and to identify individual human P450 enzymes involved in the metabolism of these PCBs. I chose chiral PCB congeners 2,2',3,4',6-pentachlorobiphenyl (PCB 91); 2,2',3,5',6-pentachlorobiphenyl (PCB 95), 2,2',3,3',4,6'-hexachlorobiphenyl (PCB 132) and 2,2',3,3',6,6'-hexachlorobiphenyl (PCB 136) for this investigation because they are environmentally relevant and their metabolism has been studied in rodents and other laboratory animal species (Kania-Korwel et al., 2016a). Prochiral PCB congeners 2,2′,4,6′-tetrachlorobiphenyl (PCB 51) and 2,2′,4,5,6′-pentachlorobiphenyl (PCB 102) were selected because their considerable presence in technical PCB mixtures. To test the hypothesis that P450 enzyme and species differences mediate the congener-specific enantioselective metabolism of chiral PCBs to hydroxylated metabolites, I sought to establish structure-metabolism relationships by studying the enantioselective metabolism of structurally diverse chiral PCBs by human liver microsomes (HLMs). Racemic PCB 91, PCB 95 and PCB 132 were incubated in vitro with pooled or individual donor HLMs at 37 °C, and levels and chiral signatures of the parent PCB and its hydroxylated metabolites were determined by high-resolution gas chromatography equipped with time-of-flight mass spectrometry (GC/TOF-MS) or electron capture detection (GC-ECD). Hydroxylated metabolites formed were identified and metabolic schemes for these PCBs proposed. I found inter-individual differences in the formation of OH-PCBs by individual donor HLMs. Comparison of the metabolite profiles of PCB 91, PCB 95, PCB 132 and PCB 136 (PCB 136 metabolism by HLMs was investigated by other researchers) revealed congener-specific differences in the oxidation of PCBs by human cytochrome P450 enzymes. PCB 91 and PCB 132 were mainly hydroxylated in meta position, with the 1,2-shift metabolites being the major metabolites formed from both PCB congeners by HLMs. In contrast, PCB 95 and PCB 136 were primarily hydroxylated in the para position. Moreover, we determined human P450 isoforms involved in the metabolism of neurotoxic PCBs using in silico and in vitro approaches. In silico predictions suggested that chiral PCBs are metabolized by CYP1A2, CYP2A6, CYP2B6, CYP2E1, and CYP3A4. Experimentally we found that CYP2A6, CYP2B6 and to a minor extent CYP2E1 were the enzymes involved in the metabolism of these chiral PCBS. We also investigated nonchiral sources of chiral OH-PCBs by studying the P450- and species-dependent biotransformation of prochiral PCB 51 and PCB 102 to chiral OH-PCB metabolites. Prochiral PCB 51 and PCB 102 were incubated with liver microsomes prepared from male Sprague-Dawley rats pretreated with various inducers of P450 enzymes including phenobarbital (PB), dexamethasone (DEX), isoniazid (INH), β-naphthoflavone (BNF), clofibric acid (CFA) or corn oil (CO); and untreated male cynomolgus monkeys, Hartley albino guinea pigs, New Zealand rabbits, golden Syrian hamsters; and untreated female Beagle dogs. PCB 51 and PCB 102 were metabolized to 2,2',4,6'-tetrachlorobiphenyl-3'-ol (OH-PCB 51) and 2,2',4,5,6'-pentachlorobiphenyl-3'-ol (OH-PCB 102), respectively. The formation of both metabolites was P450 isoforms- and species-dependent. Moreover, OH-PCB 51 and OH-PCB 102 were chiral and were formed enantioselectively in all microsomes investigated. Taken together, my findings demonstrate (1) considerable inter-individual variability in the congener-specific metabolism of PCBs to OH-PCBs; (2) the enantioselective formation of OH-PCBs by human CYP2A6, CYP2B6, and CYP2E1; and (3) that chiral PCB metabolites are formed enantioselectively from prochiral PCB congeners. Interestingly, the metabolism of PCBs by CYP2A6 appears to involve arene oxide intermediates, as suggested by the formation of 1,2-shift products as major metabolites of PCB 91 and PCB 132. In contrast, 1,2-shift products are minor PCB metabolites formed in rodents. Therefore extrapolation of hepatic metabolism across species may not be consistent and these differences should be considered in future toxicity and risk assessment studies.

Os diterpenos labdanos ácidos ent-poliáltico (AP) e ent-diidroagático (ADA) são metabólitos secundários amplamente distribuídos em diversas espécies vegetais, sendo particularmente comuns nos exsudatos extraídos dos troncos das árvores do gênero Copaifera (Leguminosae- Caesalpinioideae). Estas oleorresinas apresentam diversas atividades biológicas e são utilizadas na medicina popular desde a época dos índios pré-colombianos. Apesar de sua ampla utilização, não há estudos acerca de seu metabolismo. Estudos de biotransformação com constituintes bioativos como o AP e ADA podem contribuir para o entendimento de reações metabólicas in vivo das oleorresinas. Além de indispensáveis na fase pré-clinica de desenvolvimento e otimização de fármacos, os estudos de biotransformação in vitro também podem propiciar a obtenção de novas estruturas químicas farmacologicamente ativas. Assim, os diterpenos AP e ADA foram submetidos a estudos de biotransformação com diferentes tipos de biocatalisadores: fungos filamentosos, micro-organismos do trato gastrointestinal e microssomas hepáticos humanos. Foram obtidos quinze metabólitos de biotransformação com os fungos Cunninghamella elegans, Cunninghamella echinulata e Aspergillus brasiliensis, sendo treze estruturas ainda não descritas na literatura. A reação enzimática mais comum promovida pelos fungos sobre os diterpenoides foi a hidroxilação, porém isomerização da ligação dupla e acetilação também foram identificadas. Apesar de terem sido detectadas diminuições acentuadas nas concentrações dos diterpenos nas culturas com os microorganismos do trato gastrointestinal, os rendimentos dos processos de biotransformação na escala de produção desenvolvida não propiciaram metabólitos em concentrações satisfatórias para isolamento. Apesar dos baixos rendimentos, foi possível propor através de espectrometria de massas a estrutura de quatro derivados oxidados e/ou metilados do ADA após incubação com Saccharomyces boulardii, Lactobacillus fermentum, Escherichia coli, cultura mista com probióticos do gênero Lactobacillus e cultura mista com os probióticos do gênero Bifidobacterium. O ácido ent-agático foi identificado entre os metabólitos propostos, indicando a necessidade de mais estudos acerca do metabolismo dos constituintes das oleorresinas de Copaifera, uma vez que o ácido agático já foi reportado na literatura como abortivo em mamíferos. Para os metabólitos obtidos com microssomas hepáticos humanos foram propostas quatro estruturas oxidadas no metabolismo de fase I e quatro estruturas conjugadas com ácido glucurônico no metabolismo de fase II e fase I e II combinados. Os precursores e os derivados majoritários de biotransformação foram submetidos a ensaios de citotoxidade com células tumorais das linhagens Caco-2, HeLa e MCF-7, além da linhagem normal MCF-10A. As mudanças químicas promovidas pelos fungos na estrutura do ADA não acarretaram mudanças significativas em sua atividade biológica, enquanto a maioria dos derivados do AP apresentou menor efeito citotóxico. Apenas o metabólito P06(AP) apresentou atividade cerca de quatro vezes maior (IC50 = 62,6 ?M) que o precursor, sugerindo que a migração da dupla e a introdução de grupo acetato na estrutura do AP pode ser uma estratégia para obtenção de derivados mais ativos frente a linhagem HeLa. De modo geral, os resultados obtidos neste estudo reforçam a importância da biotransformação como estratégia para obtenção de novas estruturas químicas e contribuem para o entendimento do metabolismo de constituintes bioativos das oleorresinas medicinais de Copaifera / The labdane diterpenes ent-polyalthic (AP) and ent-dihydroagathic (ADA) acids are secondary metabolites widely spread in several plants. Both diterpenes are particularly common in the oleoresins extracted from the tree trunks of Copaifera sp. (Leguminosae- Caesalpinioideae). These oleoresins have several biological activities and have been used in folk medicine since the pre-Columbian Indians times. Despite their wide use, research on the metabolism of the oleoresins is lacking. Biotransformation studies with their bioactive constituents such as AP and ADA may contribute to the understanding of in vivo metabolic reactions. In vitro biotransformation studies are mandatory in the preclinical stage of drug development and optimization and can also provide new pharmacologically active derivatives. Given that, the diterpenes AP and ADA were submitted to biotransformation studies with different types of biocatalysts: filamentous fungi, microorganisms from the gastrointestinal tract and human liver microsomes. The biotransformation with the fungi Cunninghamella elegans, Cunninghamella echinulata and Aspergillus brasiliensis afforded two known structures and thirteen new metabolites. The most common enzymatic reaction by the fungi was hydroxylation, but isomerization of the double bond and acetylation were also detected. Although the microorganisms from the gut microbiota were able to reduce the concentration of the diterpenes in the cultures, the biotransformation yields of the processes were not enough for metabolite isolation. Despite the low yields, four oxygenated and/or methylated metabolites were proposed by mass spectrometry, after incubation of ADA with Saccharomyces boulardii, Lactobacillus fermentum, Escherichia coli, mixed culture with Lactobacillus sp. probiotics and mixed culture with Bifidobacterium sp. probiotics. The diterpene ent-agathic acid was identified among the metabolites, indicating the need for further studies on the metabolism of Copaifera oleoresin constituents, since agathic acid has already been reported as abortive in mammals. Four oxygenated structures and four metabolites conjugated with glucuronic acid were proposed for the phase I and phase II metabolism with human liver microsomes, respectively. The antiproliferative effects of the diterpenes and their major biotransformation derivatives were evaluated against the cancer cell lines Caco-2, HeLa and MCF-7 and the normal cell line MCF-10A. The chemical changes promoted by the fungi in the structure of ADA resulted in no significant changes in its biological activity. Most AP\'s derivatives displayed lower cytotoxic effects, except for the metabolite P06(AP), which showed to be four times more active (IC50 = 62.6 ?M) than its precursor. The migration of the double bond and the introduction of the acetate group in AP\'s skeleton were associated with the greater biological activity. The results obtained herein reinforce the use of biotransformation as a strategy to obtain new chemical structures and contribute to the understanding of the metabolic pathways of bioactive constituents of Copaifera medicinal oleoresins.

FORTES, S.S. Estudo de metabolismo in vitro e inibição enzimática do produto natural Licarina A empregando microssomas hepático de humanos. 2017. Tese (Doutorado) - Faculdade de Filosofia Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 2017. Muitos fármacos comercializados tiveram sua origem em produtos naturais e seus derivados. Devido ao grande potencial farmacológico destas novas moléculas pesquisadas, uma etapa importante e inicial no desenvolvimento de um novo fármaco é a avaliação do seu comportamento frente as enzimas do citocromo P450 (CYP 450), incluindo os estudos de interações medicamentosas. Neste contexto, um substrato que merece destaque é a Licarina A (Lic A). Este composto é uma neolignana encontrada em algumas espécies de plantas e vêm demonstrando várias propriedades biológicas promissoras, dentre elas destaca-se a atividade anti-leishimania. No entanto, para que esta substância com comprovada atividade se torne um fármaco é necessário realizar, na fase pré-clínica, estudos sobre seu perfil metabólico frente às enzimas do CYP450 e estudos de interação medicamentosa. Portanto, esta Tese teve como objetivo determinar os parâmetros enzimáticos utilizando microssomas hepáticos de humanos através do estudo de metabolismo in vitro com esta molécula e realizar estudos de interação medicamentosa através dos estudos de inibição enzimática e pesquisar a isoforma do CYP450 que metaboliza predominantemente este produto natural através do emprego de enzimas recombinantes de humanos. Primeiramente, foi desenvolvido um método analítico para a determinação do produto natural Licarina A em meio microssomal. As análises foram realizadas por cromatografia liquida de alta eficiência empregando a coluna Ascentis C18 e fase móvel composta por metanol: solução aquosa de ácido fórmico 0,1% (75:25, v/v); a vazão empregada foi de 1,0 mL min-1. O método foi validado na faixa de concentração de 0,383 a 76,65 ?mol L-1, com coeficiente de correlação linear de 0,99 e limite de quantificação de 0,383 ?mol L-1. A precisão e exatidão apresentaram resultados dentro do recomendável pela ANVISA. Após validação do método, estabeleceram-se as condições lineares para a depleção da Lic A no meio microssomal e posteriormente, a cinética foi determinada em condições de velocidade inicial utilizando para tanto 0,20 mg mL-1 de concentração de proteínas microssomais e 20 minutos de tempo de incubação. O comportamento observado na cinética enzimática para a depleção da Lic A foi um comportamento atípico, caracterizada pelo modelo cinético de Hill. Os valores de Vmax, S50 e coeficiente de Hill foram, 1,651 ?mol mg-1 min-1, 3,87 ?mol L-1 e 2,0 respectivamente. A partir dos parâmetros cinéticos o valor de clearance intrínseco (CLint) para a Lic A foi de 0,22 mL min-1 mg-1. Posteriormente, a correlação in vitro in vivo foi realizada e foi observado um clareance hepático (CLhep) de 20 mL min-1 kg-1 e taxa de extração hepática (E) de 1. As isoformas do CYP450 envolvidas no metabolismo da Lic A foram CYP 1A2 e 2B6. Os estudos de inibição mostraram que a Lic A é um inibidor fraco frente as isoformas do CYP450 estudadas, com valores de IC50 maiores do que 80 ?mol L-1. Embora já tenha sido estudada diferentes vias metabólicas da licarina A com vários metabólitos identificados, esta foi a primeira vez que foi observado a formação de um metabólito in vitro com o uso de microssomas hepático humano. Com o auxílio da espectrometria de massa foi possível a identificação do metabólito de m/z 343 [M+H]+, possivelmente um composto epoxidado, da licarina A. / FORTES, S.S. In vitro metabolism and enzymatic inhibition study of the natural product Licarin A employing human liver microsomes. 2017. Thesis (Doctoral) - Faculdade de Filosofia Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, 2017. Many marketed drugs had their origin in natural products and their derivatives. Due to the biological potential of these new molecules, an important initial step in the development of a new drug is the evaluation of its behavior in front of cytochrome P450 enzymes (CYP 450), including studies of drug interactions. In this context, a substrate that deserves attention is Licarin A (Lic A). This compound is a neolignan found in some species of plants and several promising biological properties have been describing for this natural product, among them anti-leishimania activity. However, for this substance to become a drug, it is necessary to perform, in the preclinical phase, studies regarding its metabolic profile and drug interactions. Therefore, this thesis aimed to determine the enzymatic parameters by using human liver microsomes through in vitro metabolism study with this molecule and to conduct drug interaction studies through the enzyme inhibition studies and finally, to investigate the CYP450 isoforms that metabolize predominantly this natural product through the use of recombinant human enzymes. Firstly, an analytical method was developed for the quantification of the natural product Licarin A in microsomal medium. The analyzes were performed by high performance liquid chromatography employing an Ascentis C18 column and mobile phase composed of methanol: 0.1% formic acid aqueous solution (75:25, v / v); the flow rate used was 1.0 mL min-1. The method was validated in the concentration range of 0.333 to 76.65 ?mol L-1, with a linear correlation coefficient of 0.99 and a quantification limit of 0.333 ?mol L-1. Accuracy and precision showed results in agreement with ANVISA guidelines. After method validation, the linear conditions for depletion of Lic A in the microsomal medium were established. Subsequently, the kinetics were determined under initial velocity conditions using 0.20 mg mL-1 of microsomal protein concentration and 20 minutes of incubation time. The behavior observed in the enzymatic kinetics for the depletion of Lic A was an atypical behavior, characterized by the Hill kinetic model. The values of Vmax, S50 and Hill coefficient were 1.651 ?mol mg-1 min-1, 3.87 ?mol L-1 and 2.0, respectively. From the kinetic parameters, the intrinsic clearance (CLint) for Lic A was 0.22 mL min-1 mg-1. Subsequently, in vitro in vivo correlation was performed and a hepatic clareance (CLhep) of 20 mL min-1 kg-1 and a hepatic extraction rate (E) of 1 was observed. The CYP450 isoforms involved in the metabolism of Lic A were CYP 1A2 and 2B6. Inhibition studies have shown that Lic A is a weak CYP450 inhibitor, with IC50 values greater than 80 ?mol L-1. Although different metabolic pathways of licanin A have been studied and several metabolites were identified, this is the first report about the formation of an in vitro metabolite after metabolism by human liver microsomes. With the aid of mass spectrometry it was possible to identify the metabolite of m/z 343 [M+H]+, possibly an epoxidized compound, of licanin A.

O miclobutanil é fungicida quiral da família dos triazóis, comercializado como mistura racêmica. Apesar dos enantiômeros apresentarem as mesmas propriedades físico-químicas, estes podem diferir em termos de atividade, metabolismo, excreção e toxicidade. No presente trabalho, foram realizados estudos in vitro enantiosseletivos de metabolismo empregando microssomas hepáticos de humanos cujos objetivos foram determinar os parâmetros cinéticos das enzimas do citocromo P450 (CYP450) após metabolismo do miclobutanil (na forma de racemato e enantiômeros isolados), determinar quais isoformas do CYP450 são responsáveis pelo metabolismo do praguicida e também a capacidade deste praguicida em inibir as principais enzimas do CYP450. Os estudos foram realizados empregando a mistura racêmica e também os enantiômeros isolados. Para tanto, foi desenvolvido e validado um método para análise enantiosseletiva do miclobutanil em meio microssomal empregando a cromatografia líquida de alta eficiência acoplada a espectrometria de massas. A separação dos enantiômeros foi realizada na coluna Chiralpak AD® empregando metanol (100%) como fase móvel. Após a validação do método, os parâmetros cinéticos foram determinados, com valores de Vmáx, Km e CLint de 66,06 + 4,59 nmol min-1 mg-1, 3,61 + 0,88 ?mol L-1 e 18,30 mL min-1 mg-1 respectivamente, quando o substrato foi o racemato e de 305,50 + 18,39 nmol min-1 mg-1, 6,85 + 1,29 ?mol L-1 e 44,60 mL min-1 mg-1 respectivamente, quando o (+)-miclobutanil foi empregado como substrato. O (?)-miclobutanil não foi metabolizado pelas enzimas presentes nos microssomas hepáticos de humanos. As isoformas responsáveis pelo metabolismo do miclobutanil foram a CYP2C19 e a CYP3A4. Os estudos in vitro de inibição mostraram que o miclobutanil é um inibidor moderado das enzimas CYP2D6 e CYP2C9 um inibidor forte das enzimas CYP3A4/5 e CYP2C19. / Myclobutanil is a chiral triazole fungicide, sold as a racemic mixture. Although the enantiomers have the same physico-chemical properties, they may exhibit different bioactivity, metabolism, excretion and toxicity. In the present work, in vitro enantioselective metabolism studies were carried out by using human liver microsomes, aiming to determine the kinetic parameters of cytochrome P450 (CYP450) enzymes after myclobutanil metabolism and the main CYP450 isoforms involved in the metabolism. In addition, the myclobutanil inhibition capacity over the main CYP450 enzymes was evaluated. The studies were carried out with rac-myclobutanil as well as with the isolated enantiomers. To accomplish that, an enantioselective method for myclobutanil analysis was developed and validated by using high performance liquid chromatography coupled with mass spectrometry. The separation of enantiomers was realized on a Chiralpak AD® column and methanol (100%) was used as mobile phase. The enzymatic kinetics, Vmáx, Km and CLint, were: 66.06 + 4.59 nmol min-1 mg-1, 3.61 + 0.88 ?mol L-1 and 18.30 mL min-1 mg-1, respectively, for rac-myclobutanil and 305.50 + 18.39 nmol min-1 mg-1, 6.85 + 1.29 ?mol L-1 and 44.60 mL min-1 mg-1, respectively, for the (+)-myclobutanil. The (?)-myclobutanil was not metabolized by CYP450 enzymes. The isoforms involved in myclobutanil metabolism were CYP2C19 and CYP3A4. In vitro inhibition studies showed that myclobutanil is a medium inhibitor of CYP2D6 and CYP2C9 enzymes and a strong inhibitor of CYP3A4/A5 and CYP2C19 enzymes.